Last reviewed · How we verify

Hypertonic Saline 3%

Hospital General Naval de Alta Especialidad - Escuela Medico Naval · FDA-approved active Small molecule Under review

Hypertonic Saline 3% is a Osmotic agent / Hypertonic solution Small molecule drug developed by Hospital General Naval de Alta Especialidad - Escuela Medico Naval. It is currently FDA-approved for Cerebral edema and elevated intracranial pressure, Traumatic brain injury, Acute stroke with cerebral edema. Also known as: HS3%, hypertonic saline, 3% saline.

Hypertonic saline 3% draws fluid from intracellular and interstitial spaces into the intravascular compartment through osmotic gradient, reducing intracranial pressure and cellular edema.

Hypertonic saline 3% has been studied as a treatment for various conditions, including bronchiolitis, ascites, cirrhosis, and head injury in pediatric patients. It has been investigated as a nebulized solution, administered intravenously, or compared to standard treatments such as intravenous furosemide.

At a glance

Generic nameHypertonic Saline 3%
Also known asHS3%, hypertonic saline, 3% saline
SponsorHospital General Naval de Alta Especialidad - Escuela Medico Naval
Drug classOsmotic agent / Hypertonic solution
ModalitySmall molecule
Therapeutic areaCritical Care / Neurology
PhaseFDA-approved

Mechanism of action

The 3% sodium chloride solution creates an osmotic gradient that pulls water across cell membranes and from the interstitium into the bloodstream, thereby reducing brain edema and intracranial pressure. This osmotic diuretic effect is used acutely to manage elevated intracranial pressure and cerebral edema. The mechanism is purely physical/osmotic rather than receptor-mediated.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hypertonic Saline 3%

What is Hypertonic Saline 3%?

Hypertonic Saline 3% is a Osmotic agent / Hypertonic solution drug developed by Hospital General Naval de Alta Especialidad - Escuela Medico Naval, indicated for Cerebral edema and elevated intracranial pressure, Traumatic brain injury, Acute stroke with cerebral edema.

How does Hypertonic Saline 3% work?

Hypertonic saline 3% draws fluid from intracellular and interstitial spaces into the intravascular compartment through osmotic gradient, reducing intracranial pressure and cellular edema.

What is Hypertonic Saline 3% used for?

Hypertonic Saline 3% is indicated for Cerebral edema and elevated intracranial pressure, Traumatic brain injury, Acute stroke with cerebral edema, Intracranial hypertension.

Who makes Hypertonic Saline 3%?

Hypertonic Saline 3% is developed and marketed by Hospital General Naval de Alta Especialidad - Escuela Medico Naval (see full Hospital General Naval de Alta Especialidad - Escuela Medico Naval pipeline at /company/hospital-general-naval-de-alta-especialidad-escuela-medico-naval).

Is Hypertonic Saline 3% also known as anything else?

Hypertonic Saline 3% is also known as HS3%, hypertonic saline, 3% saline.

What drug class is Hypertonic Saline 3% in?

Hypertonic Saline 3% belongs to the Osmotic agent / Hypertonic solution class. See all Osmotic agent / Hypertonic solution drugs at /class/osmotic-agent-hypertonic-solution.

What development phase is Hypertonic Saline 3% in?

Hypertonic Saline 3% is FDA-approved (marketed).

What are the side effects of Hypertonic Saline 3%?

Common side effects of Hypertonic Saline 3% include Hypernatremia, Hyperchloremia, Phlebitis at infusion site, Rebound intracranial pressure elevation, Dehydration.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing